Please assess the completion status of the following clinical trial:

Trial Title: Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes in male or female patients~* Between 18 and 75 years of age~* With a HbA1c greater than or equal to 7.5% and less than 10.5% at randomization~Exclusion Criteria:~* Type 1 diabetics or type 2 diabetics currently on insulin therapy~* Patients unwilling or unable to discontinue their anti-diabetic medication(s)~* History of ketoacidosis~* History of therapy with rosiglitazone, troglitazone, pioglitazone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).